Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7633MR)

This product GTTS-WQ7633MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TNFRSF10B gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_003842.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8795
UniProt ID O14763
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ7633MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ9257MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMMU-130
GTTS-WQ1714MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA aDabi-Fab
GTTS-WQ3640MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY 1187982
GTTS-WQ3082MR IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Anti-TFPI
GTTS-WQ3321MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ASN-100
GTTS-WQ15994MR IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ZTS-00521505
GTTS-WQ9052MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IMC-18F1
GTTS-WQ3145MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA APT070
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW